Tm Bioscience Licenses Intellectual Property From Abbott
News Oct 04, 2005
Tm Bioscience Corporation has announced that it has concluded a license agreement with Abbott for certain intellectual property in the areas of, among others, human and pathogen genotyping.
The non-exclusive license is worldwide, expires co-terminously with the associated patents and covers Tm's current and future products in all fields of use.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.